Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DD25UM
|
|||
| Drug Name |
177Lu-labelled NeoBOMB1
|
|||
| Drug Type |
Radiopharmaceutical therapy agent
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 2 | [1] | |
| Company |
Novartis/AAA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastrin-releasing peptide receptor (GRPR) | Target Info | . | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03724253) [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR) (NeoFIND). U.S. National Institutes of Health. | |||
| REF 2 | 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.